RJA
GILD icon

Ross\Johnson & Associates’s Gilead Sciences GILD Stock Holding History

Ross\Johnson & Associates’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$379 Buy
3
+2
+200% +$264 0.01% 166
2026
Q1 		$139 Sell
1
-1
-50% -$140 ﹤0.01% 194
2025
Q4 		$245 Buy
2
+1
+100% +$122 ﹤0.01% 228
2025
Q3 		$111 Hold
1
– – ﹤0.01% 197
2025
Q2 		$111 Sell
1
-18
-95% -$1.92K ﹤0.01% 195
2025
Q1 		$2.13K Buy
+19
New +$1.96K 0.04% 162

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ross\Johnson & Associates's GILD Position: Q2 2026 in Review

Ross\Johnson & Associates increased its Gilead Sciences (GILD) stake by 200% in Q2 2026, buying an estimated $264 and bringing the position to 3 shares worth $379. The position accounts for 0.01% of the portfolio, ranked #166.

Ross\Johnson & Associates first reported a position in GILD in Q1 2025 and has held it in 6 quarters since. The position peaked at $2.13K in Q1 2025. 2,274 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Ross\Johnson & Associates held 3 shares of Gilead Sciences worth $379 as of Q2 2026.
  • Ross\Johnson & Associates bought 2 Gilead Sciences shares in Q2 2026, an estimated $264.
  • Gilead Sciences made up 0.01% of Ross\Johnson & Associates's portfolio in Q2 2026, its #166 holding.
  • Ross\Johnson & Associates first reported a position in Gilead Sciences in Q1 2025 and has held it in 6 quarters since.
  • Ross\Johnson & Associates's Gilead Sciences position peaked at $2.13K in Q1 2025.
  • 2,274 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Ross\Johnson & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.